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Abstract
Introduction Genomic aberrations in the form of
subchromosomal DNA copy number changes are a hallmark of
epithelial cancers, including breast cancer. The goal of the
present study was to analyze such aberrations in breast cancer
at high resolution.
Methods We employed high-resolution array comparative
genomic hybridization with 4,134 bacterial artificial
chromosomes that cover the genome at 0.9 megabase
resolution to analyze 47 primary breast tumors and 18 breast
cancer cell lines.
Results Common amplicons included 8q24.3 (amplified in 79%
of tumors, with 5/47 exhibiting high level amplification), 1q32.1
and 16p13.3 (amplified in 66% and 57% of tumors,
respectively). Moreover, we found several positive correlations
between specific amplicons from different chromosomes,
suggesting the existence of cooperating genetic loci. Queried
by gene, the most frequently amplified kinase was PTK2 (79%
of tumors), whereas the most frequently lost kinase was PTK2B
(hemizygous loss in 34% of tumors). Amplification of ERBB2 as
measured by comparative genomic hybridization (CGH)
correlated closely with ERBB2 DNA and RNA levels measured
by quantitative PCR as well as with ERBB2 protein levels. The
overall frequency of recurrent losses was lower, with no region
lost in more than 50% of tumors; the most frequently lost tumor
suppressor gene was RB1 (hemizygous loss in 26% of tumors).
Finally, we find that specific copy number changes in cell lines
closely mimicked those in primary tumors, with an overall
Pearson correlation coefficient of 0.843 for gains and 0.734 for
losses.
Conclusion High resolution CGH analysis of breast cancer
reveals several regions where DNA copy number is commonly
gained or lost, that non-random correlations between specific
amplicons exist, and that specific genetic alterations are
maintained in breast cancer cell lines despite repeat passage in
tissue culture. These observations suggest that genes within
these regions are critical to the malignant phenotype and may
thus serve as future therapeutic targets.
Introduction
Genomic instability is a hallmark of cancer, and specific
subchromosomal copy number changes are thought to play a
driving role in the transformation of normal cells to malignant
clones. These genomic copy number changes may result in
deletion of one or both alleles of tumor suppressor genes,
overexpression of oncogenes and rearrangements that may
alter transcription of target and downstream genes (reviewed
in [1]). Several recent studies suggest that fixed genetic
abnormalities in human cancers may be highly predictive of
response to targeted therapeutics. For example, ERBB2
amplification may be more predictive of response to trastuzu-
mab than protein overexpression with normal gene copy
number (reviewed in [2]), and activating mutations in EGFR
determine response to gefitinib [3,4].
aCGH = array-based comparative genomic hybridization; BAC = bacterial artificial chromosome; CGH = comparative genomic hybridization; CRO 
= common region of overlap; EGF = epidermal growth factor; IDC = infiltrating ductal carcinoma; ILC = infiltrating lobular carcinoma; IR = intensity 
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There is an extensive literature on DNA copy number altera-
tions in cancer using low resolution technology such as PCR-
based allelotyping, spectral karyotyping, and metaphase com-
parative genomic hybridization (CGH). These studies, how-
ever, are limited in their ability to characterize specific
abnormalities across the genome and to identify altered genes
within the large regions defined by these methodologies.
Nonetheless, when considering the breast cancer literature,
these studies are consistent, frequently reporting the same
regions of gain (1q, 8q, 11q, 17q, 20q) and loss (6q, 8p, 9p,
13q, 16q) [5-11].
More recent studies have employed higher resolution array-
based CGH (aCGH) to characterize primary tumors [10,12-
14]. These studies demonstrate the enormous complexity of
cancer genomes, but also provide evidence that consistent,
non-random patterns of copy number alterations are present in
human cancers and support the hypothesis that selection for
genomic changes conferring a proliferative advantage plays an
important role in malignant transformation.
To further characterize the genomic alterations that may drive
both transformation and response to targeted therapies, we
developed an aCGH platform that covers the genome at 0.9
megabase (Mb) resolution [15]. Here we report the use of
these arrays to define the genomic profile of 47 primary breast
tumors and 18 breast cancer cell lines. Specifically, we evalu-
ated the most common regions of gain and loss across the
genome, assessed correlations with clinical parameters, char-
acterized the ERRB2 locus and pathway in detail, and identi-
fied potentially cooperating genetic loci.
Materials and methods
Cell lines and tumor samples
Eighteen breast cancer cell lines (BT-20, HCC1143,
HCC1187, HCC1395, HCC1419, HCC1569, HCC1599,
HCC1937, HCC1954, HCC202, HCC2218, HCC38, MDA-
MB-134-VI, MDA-MB-157, MDA-MB-361, MDA-MB-415,
SKBR-3, and T-47D) were obtained from American Type Cul-
ture Collection (Manassas, VA, USA). Forty-seven fresh-frozen
primary breast tumors (thirty-nine infiltrating ductal carcinoma
(IDC), two infiltrating lobular carcinoma (ILC), four mixed IDC/
ILC, two ductal carcinoma in situ) were obtained from St Fran-
cis Hospital (Wilmington, DE, USA). Tissue and data collec-
tion were performed with patient consent as approved by the
Institutional Review Boards of both The University of Pennsyl-
vania and St Francis Hospital institutions. Tumors not required
for diagnosis were frozen in liquid nitrogen and used for further
study. Clinical data and tumor characteristics are provided in
Additional file 1.
DNA copy number detection
Hematoxylin and eosin staining was used to define a region of
tissue containing at least 70% tumor, which was dissected
away from normal tissue using a scalpel. Thirty 20 µm sections
were used for DNA isolation by proteinase K digestion fol-
lowed by phenol/chloroform extraction in PhaseLock Gel
tubes (Eppendorf, Westbury, NY, USA). An additional hema-
toxylin and eosin stained section was used to verify the persist-
ence of at least 70% tumor in the residual tissue adjacent to
the sectioned area. Normal genomic DNA, used as the refer-
ence probe for aCGH co-hybridization, was prepared from
peripheral leukocytes of healthy female volunteers of diverse
ethnic backgrounds using alkaline lysis. DNA from at least five
donors was pooled equally before labeling.
CGH arrays were prepared using degenerate oligonucleotide-
primed PCR products from 4,134 bacterial artificial chromo-
some (BAC) clones printed in triplicate on glass slides (Ultra
GAPS, Corning, Acton, MA, USA) [15].
For hybridization, 1 µg of test DNA and 1 µg of pooled normal
human DNA were labeled with either Cy3-dCTP or Cy5-dCTP
incorporated by random priming (Bioprime Labeling Kit, Invit-
rogen, Carlsbad, CA, USA). After overnight incubation at
37°C, labeling reactions were purified (MinElute PCR Clean-
up, Qiagen, Valencia, CA, USA), and the tumor and normal
DNAs combined and ethanol-precipitated with 100 µg human
Cot-1 DNA (Invitrogen). DNAs were rehydrated in 50 µl of for-
mamide-based hybridization buffer [16], denatured at 70°C for
15 minutes and re-annealed for 30 minutes at 37°C to block
repetitive sequences. Tumor and normal DNAs were then co-
hybridized to the CGH arrays at 37°C for 72 h on a rotating
platform and washed as described by Gray and colleagues
[16]. For each sample, the test and reference DNA also were
labeled with the opposite dye in a separate experiment ('dye
swap') to account for differences in dye incorporation and pro-
vide additional data points for analysis.
Arrays were scanned on a GenePix 4000B scanner (Axon
Instruments, Downingtown, PA, USA) and the composite tiff
image was segmented using GenePix Pro 4.0 (Axon Instru-
ments). Foreground (signal) and background intensities were
generated separately for Cy3 and Cy5 channels, and the local
background intensity was subtracted to generate a corrected
intensity for each spot. The ratio of background corrected Cy3
to Cy5 values was then calculated for each spot and, because
each BAC clone was printed on the array three times, these
measurements were averaged to generate the intensity ratio
(IR) for the clone. Two arrays (dye swap) were hybridized for
each sample; therefore, a total of six measurements determine
the relative DNA copy number of each BAC clone in the test
sample relative to the reference sample.
Data were normalized and visualized using CGHAnalyzer [15],
which is available for download from CGHcloneDB [17]. Copy
number deviations from diploid were determined by BACs
with IRs that differed significantly from a normal distribution
representing diploid copy number which was developed using
50 normal:normal genomic DNA hybridizations on these arraysAvailable online http://breast-cancer-research.com/content/7/6/R1186
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[15] (>2 standard deviations for both replicates). We use the
following thresholds and terms throughout the text: IR >2.0
(high-level copy number gain, >5 copies), IR <0.5
(homozygous deletion).
DNA and transcript copy number validation
Genomic copy number alterations of selected regions were
validated using a relative quantitative (Q)-PCR assay. For the
ERBB2 region, the LightCycler HER2/neu DNA Quantifica-
tion Kit (Roche, Nutley, NJ, USA) was used. An additional 50
× 20 µm sections were cut from 18 primary tumors (15 IDC,
one mixed IDC/ILC, two ductal carcinoma in situ) directly into
Trizol for RNA extraction and the RNA was further purified
using the RNeasy Kit (Qiagen). ERBB2 transcript levels were
determined using the High Capacity cDNA Archive Kit, and a
TaqMan©  Microfluidic Card Assay on Demand (Hs.
00170433_m1; Applied Biosystems, Foster City, CA, USA).
The 18S ribosomal subunit assay (Hs. 99999904_m1) was
used as a control.
DNA copy number for PTK2 (chromosome 8, 141,639,559 to
141,781,701 bases) was determined by real-time Q-PCR
using TaqMan Universal PCR master mix and TaqMan prim-
ers/probe designed using Primer Express software (Applied
Biosystems). The data were collected using the Applied Bio-
systems Prism 7900HT Sequence Detection System, ana-
lyzed with SDS v2.1 and Excel (Microsoft Corp., Redmond,
WA, USA). PTK2 levels are reported relative to TBP (TATA
box binding protein), which is diploid in the breast tumors.
Primers used were: PTK2-QF, 5'
TGACTATTTTACAGCCACTGGAGTTAA3'; PTK2-QR, 5'
GAAAACCAAATTCCTGTTTTGCTT 3'; PTK2-QP: 5'FAM
ACCCTTCCTTGTATCTGTCTTCCCAGGAGA TAMRA 3'.
These data were directly compared to aCGH data from a BAC
clone covering the PTK2 locus (RP11-502G13; chromosome
8, 142,176,518 to 142,176,951 bases) and several neighbor-
ing BACS. The concordance of these data was assessed by a
t-test between the Taqman© data for those samples with and
without high-level gains (BAC clone IR >2.0).
Statistical analysis
As only a portion of the genome is directly covered by BAC
clones on this array, a flanking region algorithm built into
CGHAnalyzer extrapolates copy number estimations in uncov-
ered regions between BAC clones. This extrapolates the
extent of the copy number alteration represented by a given
BAC to the genomic coordinate of the neighboring BAC clone
of a different estimated copy number. This approach avoids
missing important genetic changes between BACs but, by
definition, overestimates the size of alterations. Consecutive
BAC clones that are designated as being similarly altered are
merged into a single representative region of change. The
resultant data structure for a single sample is simply a series
of genomic regions designated as either gained or lost. Pear-
son correlation coefficients were used to evaluate similarities
(positive correlations) and differences (negative correlations)
in copy number alteration trends within and across data sets
(e.g., cell lines versus tumors). Pearson correlations were cal-
culated by weighting the alteration frequency of each locus on
a linear scale. Further, all correlations were compared to the
distribution of correlations where the copy number alterations
were arranged randomly (n = 1,000). To estimate the total por-
tion of the genome gained or lost, each segment was summed
and divided by 2,679 Mb, the total Mb in the genome (exclud-
ing heterochromatic, centromeric and telomeric regions not
covered by BACs, and the sex chromosomes). The Wilcoxon
rank sum test was used to compare estimates between tumors
and cell lines, as well as between tumor subsets.
Correlation matrices were generated to identify the intersec-
tion of changes at two loci by a binomial probability-based
metric. Specifically, the relative correlation of two loci was
scored by their pair-wise comparison based on the genomic
regions data structure, and defined in terms of the probability
of the number of samples sharing aberrations at two loci if they
were distributed among the samples by chance. The Fisher's
exact test was used with permutation analysis to determine the
statistical significance of the correlation between the most fre-
quently aberrant loci in the data set. Multiple iterations (n =
2,000) were performed and the lowest p-values from these
randomized iterations were compared to the p-values from the
experimental data. Loci were considered significantly corre-
lated when the associated p-value was less than the lowest p-
value from the randomized data.
Results
As the initial step in our analysis, we reviewed the existing lit-
erature on whole genome DNA copy number analysis of
human breast cancers; four chromosomal CGH studies [5-8]
and two array-based CGH studies [9,10] were used for com-
parison (Table 1). All studies identified recurrent gains on
chromosomes 1q, 8q, 11q, 17q, 20q, and losses on 6q, 8p,
9p, 13q, 16q. However, our high-resolution arrays detected a
higher percentage of tumors with these gains, as well as sev-
eral high-level amplifications (IR >2, estimated >5 copies), in
these regions. For example, six previous studies [5-10] sug-
gest that 40% to 50% of primary breast tumors have copy
number gains of chromosome 8q24; however, this region was
amplified in 79% of the tumors in the current study. Our aCGH
arrays also identified five regions of gain in more than 50%,
and four regions of loss in more than 30% of tumors that have
not been previously associated with breast cancer (Table 1).
Comparison of primary tumors and cell lines
We compared the location, frequency and size of copy
number changes in primary tumors versus cell lines. Surpris-
ingly, the location of more frequent gains and losses in the cell
lines very closely mirrored those in the primary tumors (Fig. 1).
This is demonstrated by a Pearson correlation coefficient ofBreast Cancer Research    Vol 7 No 6    Naylor et al.
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0.843 for gains and 0.734 for losses. The mean correlation of
randomly placed gains was 0.295 (σ = 0.078) and losses was
0.203 (σ = 0.082), which yield p < 0.0001 for the tumor ver-
sus cell line correlations for both cases when modeled to a
normal distribution. Additionally, there appeared to be more
alterations in cell lines. Primary tumors had gains involving a
mean of 410.8 Mb (14.5%) of the genome, which was signifi-
cantly greater than that seen in cell lines (µ = 674.2 Mb
(23.8%), σ = 243.6 Mb (8.6%); p = 0.0014). Similarly, losses
in primary tumors (µ = 286.1 Mb (10.1%), σ = 195.5 Mb
(6.9%)) were less extensive than those seen in cell lines (µ =
589.3 Mb (20.8%), σ = 226.6 Mb (8.0%); p = 0.0001). As
Table 1
Frequent DNA copy number alterations in breast cancer: previous reports compared with the current study
Genomic 
change
Previous reports Current study
Reference Region % 
Tumors
Cytobanda Start (Mb)a,b Stop 
(Mb)a,b
Size 
(Mb)a,b
% 
Tumors
Cancer genes
Gains
1q+ 1p36.32 2.0 6.0 4.0 49
1q+ 1q23.3 158.8 159.6 0.8 57
1q+ [5-10] 1q32 48–67 1q32.1 202.1 202.9 0.8 66
1q+ 1q42.12-42.13 221.8 225.9 4.1 53
4p+ 4p16.1 7.1 8.8 1.7 51
5p+ [6] 5p12-14 24 5p15.33 0 1.9 1.9 49 TERT
8q+ [5-10] 8q22-qter 39–49 8q24.3 139.3 144.8 5.6 79 PTK2
9q+ 9q34.13-34.3 130.5 135.2 4.6 53 TSC1 RALGDS
16p+ [6] 16p 38–40 16p13.3 3.2 3.3 0.1 57 MMP25
17q+ [6-10] 17q12 18–60 17q12 33.6 38.9 5.3 45 TAF15 MLLT6 ERBB2
17q+ [5-10] 17q22-25 18–60 17q25.3 77.7 81.1 3.5 45 GRB2 TIMP2
20q+ [5-10] 20q13 18–44 20q13.12 43.8 45.7 1.9 49 MMP9
Losses
4q- 4q31.1-31.21 141.6 145.2 3.6 40
4q- 4q32 156.1 160.1 4.0 36
4q- 4q32.2 162.9 164.2 1.3 32
8p- [7] 8p22-23 20 8p23.1-23.2 4.8 7.6 2.8 40
8p- [6,8,10] 8p 18–29 8p21.3 19.9 20.0 0.1 32
8p21.2 23.5 27.5 4.0 36 PTK2B
8p12 34.8 35.6 0.8 32
9p- [6,7,9] 9p22-24 20–23 9p21.2 27.6 27.9 0.3 30
13q- [6-8,10] 13q21-31; 
13q22-31
18–57 13q14.13 44.6 45.1 0.5 30 LCP1
16q- [6-8] 16q21-qter; 
16q23-24
20–38 16q21 61.5 63.5 2.0 34 CDH8
17p- 17p12 11.5 11.6 0.1 32
18p- 18p11.31-11.23 6.1 7.6 1.5 36
21q- 21q11.2-21.1 15.3 15.9 0.6 32
Regions of gain and loss identified in previous studies are shown in comparison to those regions as detected in the present study. aMap positions 
and cytogenetic locations are based on data available from UCSC genome browser (July 2003 freeze) [35]. bRegion boundaries were determined 
by the next bacterial artificial chromosome with different copy number.Available online http://breast-cancer-research.com/content/7/6/R1186
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expected, the overall aberration rate was lower for primary
tumors (µ = 696.9 Mb (24.6%), σ = 255.0 Mb (14.5%)) than
cell lines (µ = 1269.2 Mb (44.8%), σ = 433.4 Mb (15.3%); p
< 0.0001).
Frequent amplifications
We identified 55 regions of gain present in more than 30% of
the primary tumors (Additional file 2), ranging in size from 0.1
to 8.7 Mb (median 2.1 Mb). Of those 55 regions, 20 encom-
passed a region of estimated high-level copy number change
with an IR >2 (range 2.1 to 8.7) in more than one tumor (Table
2). Several of these regions contain genes known to be ampli-
fied in breast cancer, including ERBB2,  EGFR  and  MYC,
while others include genes not previously implicated in breast
cancer, including PTK2.
The most frequently gained region in this sample set is chro-
mosome 8q24. Metaphase CGH suggests that this region is
a single amplicon, but with the increased resolution of aCGH,
two distinct regions of gain become apparent (Fig. 2). The
centromeric amplicon extends from 117.8 to 125.8 Mb
(8q24.11-24.13), has a minimal common region of overlap
(CRO) of 8.7 Mb, and is present in 20/47 tumors (43%) and
14/18 cell lines (78%). This CRO contains MYC and 23 other
genes. Two of the 20 primary tumors and 3/18 cell lines with
gains in this region have estimated high-level gains. The telo-
meric 8q24 amplicon extends from 139.3 to 144.8 Mb
(8q24.3), and has a minimal CRO of 5.6 Mb. This is the most
commonly gained region in the sample set, found in 37/47 pri-
mary tumors (79%) and 15/18 cell lines (83%). In this region,
5/47 primary tumors and 10/18 cell lines have high level copy
number gains. This region includes PTK2 (FAK) as well as
GPR20, BAI1, ARC, JRK, PSCA, ARS, LYNX1, LY6D, GML,
CYP11B1,  CYP11B2,  LY6E,  HHCM,  LY6H,  TOP1MT,
RHPN1, COL22A1, KCNK9, CHRAC1, and EIF2C2.
Two other regions of copy number gains were detected in
more than 50% of primary tumors. These regions are chromo-
some 1q32.1 (202.1 to 202.9 Mb, CRO 0.8 Mb), found in 31/
47 of primary tumors (66%), and chromosome 16p13.3 (3.2
to 3.3 Mb, CRO 0.1 Mb) found in 27/47 primary tumors
(57%). These gains were found in 14/18 (78%) and 11/18
cell lines (61%), respectively. The region on 1q32.1 contains
CNTN2,  RBBP5,  DustyPK,  HUCEP11,  SNARK,  PCTK3,
Figure 1
Array-based comparative genomic hybridization frequency plots of breast tumors and cell lines Array-based comparative genomic hybridization frequency plots of breast tumors and cell lines. Plots of primary breast tumors (light) overlaid onto 
breast cell lines (dark) with gains in green and losses in red.Breast Cancer Research    Vol 7 No 6    Naylor et al.
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ELK4, Prostein, and NUCKS. The region on 16p13.3 contains
ZNF205, ZNF215 and ZNF200. The region on 17q12 con-
taining ERBB2 (33.6 to 38.9 Mb, CRO 5.3 Mb) was also a
commonly gained region in the primary tumors, with increased
copy number detected in 21/47 primary tumors (45%) and
12/18 cell lines (67%). Three primary tumors and two cell lines
had high-level gains.
Frequent deletions
The frequency of recurrent losses was lower than that of gains;
no region was lost in more than 50% of primary tumors (Table
1). There were 13 regions of hemizygous loss found in at least
30% of tumors. These regions had CROs ranging in size from
0.1 to 4.0 Mb (median 1.3 Mb).
The two most frequently deleted regions occurred in 40% (19/
47) of the primary tumors. The first, 8p23.1-23.2 (4.8 to 7.6
Mb, CRO 2.8 Mb), contains LPAAT-e, SPAG11 and many
members of the defensin family. This region was deleted in 15/
18 cell lines (83%). Of note, three of these cell lines had an IR
<0.5, which is indicative of a homozygous deletion. The sec-
ond, 4q31.1-31.21 (141.6 to 145.2 Mb, CRO 3.6 Mb), con-
tains a region not previously described as frequently deleted in
breast cancer. This region was deleted in 6/18 cell lines
(33%), and contains six known genes: SCOC, CLGN, UCP1,
ZNF330, IL15, and INPP4B.
The only putative homozygous deletion in a primary tumor (IR
<0.5 within a region of hemizygous loss) was on 9p21.2 (27.6
to 27.9 Mb) and was seen in 2/47 primary tumors and 2/18
cell lines. This region contains ELAV,  PLAA,  CCDC2,
LRRC19, TEK, MOB3B, and IFNK. In contrast, we identified
57 putative homozygous deletions in cell lines. There were
several recurring homozygous deletions; two were found in
three cell lines and eight were found in two cell lines (Table 3).
The size of these regions ranged from 0.1 to 6.0 Mb (median
3.2 Mb). All of the recurrent homozygous deletions occurred
in regions of hemizygous loss detected in >10% of primary
tumors (median 23.5%; range 13% to 40%). Three of the
putative recurrent homozygous deletions contain a known can-
Table 2
Regions of high-level copy number gain
Chromosome Region (Mb)a,b Cell lines IR > 2 Tumors IR > 2 Tumors IR 1.2–2.0 Cancer genes
1 158.8–159.6 0 2 (4%) 29 (61.7%)
1 202.1 4 (22%) 4 (9%) 31 (66.0%) KISS1
4 6.9 1 (6%) 2 (4%) 22 (46.8%)
6 11.2–15.6 0 2 (4%) (%)
6 139.6–143.6 0 2 (4%) (%)
7 54.4–57.1 2 (11%) 2 (4%) 12 (25.5%) EGFR
8 0.1–0.3 1 (6%) 2 (4%) 31 (66.0%)
8 36.9–42.0 1 (6%) 4 (9%) 13 (27.7%) WHSCIL1, FGFR
8 74.0–75.1 1 (6%) 2 (4%) 11 (23.4%)
8 123.8–127.5 3 (17%) 2 (4%) 20 (42.6%) MYC
8 139.3–144.8 10 (56%) 5 (11%) 37 (78.7%) PTK2
11 58.8–61.3 0 3 (6%)
11 66.1–71.5 1 (6%) 2 (4%) DDB1
11 73.4–77.5 1 (6%) 2 (4%) WNT11, PAK1
13 111.4–112.9 4 (22%) 4 (9%) 21 (44.7%) GAS6
17 35.1–38.3 2 (11%) 5 (11%) 17 (36.2%) TAF15, MLLT6, 
ERBB2
17 58.1–60.4 2 (11%) 2 (4%) 10 (21.3%) PPM1D
20 43.8–45.9 4 (22%) 3 (6%) 5 (10.6%) MMP9
20 49.2–50.0 2 (11%) 2 (4%)
21 45.1–45.8 3 (17%) 5 (11%) 18 (38.3%) ITGB2
Regions of copy number gain containing more than one amplification with intensity ratio (IR) >2.0, as well as frequency of single copy gain (IR 
1.2–2.0) in these regions. aMap positions and cytogenetic locations are based on data available from UCSC genome browser (July 2003 freeze) 
[35]. bRegion boundaries were determined by the next bacterial artificial chromosome with different copy number.Available online http://breast-cancer-research.com/content/7/6/R1186
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cer-related gene; 8p22-21.3 (17.9 to 22.0 Mb; PCM1),
8p21.2 (23.0 to 27.1 Mb; TNFRS10A) and 18q21.1-21.2
(46.8 to 52.8 Mb; MADH4) (cancer gene list queried from
[15]). None of these regions contain known fragile sites.
Correlation of genomic alterations with clinical 
characteristics
Based on the flanking region approach to copy number alter-
ation estimation, the mean percent of the genome gained and
lost was calculated for each of the tumor subgroups (e.g.,
estrogen receptor positive versus negative) and differences
evaluated using the Wilcoxon rank sum test (Additional file 3).
In this sample set, total percentage of the genome altered did
not vary significantly by stage (p = 0.79), grade (p = 0.12),
ERBB2 status (p = 0.48), ER status (p = 0.23), menopausal
status (p = 0.89), or DNA ploidy (p = 0.70). Similar results
were observed when individually evaluating the percentage of
the genome gained or lost. No obvious correlations between
specific gains or losses were observed, possibly as a result of
small numbers of patients in each subgroup in relation to a
large number of aberrations.
Genes with frequent copy number changes
We queried the frequency of copy number changes in all
known genes, as well as the following gene classes; tumor
suppressor genes [18], kinases [19], and cancer-related
genes adapted from work by Futreal and colleagues [15,20].
The 10 most frequent gains and losses for each gene class are
shown in Additional file 4 (complete list available on request).
RB1 was the most frequently lost tumor suppressor gene,
hemizygously deleted in 12/47 primary tumors (26%) and 9/
18 cell lines (50%). RB1 copy number gains were not seen in
any primary tumors and only 1/18 cell lines (5.6%).
The ten most frequently amplified kinases were gained at least
six times more frequently than lost, likely indicating a selection
for gains of these genes. PTK2  was the most frequently
gained gene on both the kinase and cancer-related gene list,
amplified in 37/47 primary tumors (79%) and 15/18 cell lines
(83%). PTK2 was never deleted in the primary tumors and
deleted in only 2/18 cell lines (11%). Amplification of the
PTK2 gene within the amplified locus was further analyzed by
Taqman quantification, and DNA levels in samples that had
amplified PTK2 (IR >2.0 by aCGH) were significantly higher
than levels in unamplified samples (p = 0.0018; data not
shown). Interestingly, five kinases (PTK2B,  PHKB,
DCAMKL1, TEK, MAP2K4) were deleted at least five times
more frequently than gained, suggesting these kinases may
play a role in negatively regulating growth. Of note, inactivating
mutations in MAP2K4 have been identified in 5% of breast
cancers [19]. Additionally, PTK2B is both the most frequently
lost kinase and cancer-related gene, hemizygously deleted in
Figure 2
Comparative genomic hybridization analyzer view of chromosome 8 Comparative genomic hybridization analyzer view of chromosome 8. Tumors are displayed vertically and bacterial artificial chromosomes (BACS) by 
genome position horizontally. Low-level gains (ratio between 1.2 and 2.0) are green, high-level amplifications (ratio >2.0) are yellow, and single copy 
losses are red. Boxes surround common areas of aberration listed in Table 1. All BAC clone, gene and cytoband locations are given in megabase 
coordinates based on the UCSC genome browser (July 2003 freeze) [35].Breast Cancer Research    Vol 7 No 6    Naylor et al.
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16/47 tumors (34%), and 12/18 cell lines (67%). The remain-
ing five of the ten most frequently deleted kinases are found
with equal frequency in regions of gain and loss, an indication
that copy number changes in these genes are not likely to be
functionally significant and consistent with the idea that most
kinases confer a proliferative advantage.
Tumor suppressor genes and kinases are subsets of the can-
cer-related gene list, so it is not surprising that seven of the top
ten cancer-related gene gains are kinases. However, there are
three cancer-related genes (GRB2, GAS6, MLLT6) found in
regions of gain at least five times more frequently than lost that
are not kinases. GRB2, an adaptor molecule in the epidermal
growth factor (EGF) signaling pathway, is gained in 22/47 pri-
mary tumors (47%) and 12/47 cell lines (67%). GAS6, the
ligand of the tyrosine kinase AXL, is gained in 21/47 primary
tumors (45%) and 12/47 cell lines (67%). Two cancer-related
genes (RBL2 and CDH8) are three times more frequently lost
than gained. RBL2/p130 is deleted in 14/47 primary tumors
(30%) and 10/18 cell lines (56%).
Correlation of ERBB2 DNA, RNA and protein levels
We identified five distinct regions of gain on chr17q, including
the ERBB2 locus at 17q12. Because of the clinical signifi-
cance of this gene, we determined ERBB2 genomic DNA
copy number (Q-PCR LightCycler) and mRNA transcript lev-
els (Taqman) in the subset of 13 primary tumors for which clin-
ically obtained Hercept test data and adequate RNA were
available (Table 4). Consistent with the previously reported fre-
quency of ERBB2 overexpression in primary breast tumors of
approximately 30% (reviewed in [2]), four of these 13 primary
tumors had a positive Hercep test (2+ or 3+) reported by a
clinical lab. The two tumors with 3+ staining intensity also had
IR >2 for the BAC clone closest to ERBB2 on the CGH array
(RP11-552K3) and had a Q-PCR relative ratio >1.5, validating
the aCGH data. These tumors also showed overexpression of
ERBB2  mRNA compared to regions without copy number
increase, with a TaqMan ratio >5.
Pathway mapping of aCGH data
As noted above, the EGF/ERBB2 signaling pathway is clini-
cally relevant in breast cancer. We thus used GenMapp [21]
to visualize a composite analysis of DNA copy number of this
pathway (Fig. 3). Of note, one or more genes in the canonical
EGF signaling pathway were altered in 39/47 primary tumors
(83%). Three genes in this pathway had IRs >2 in our set of
47 primary tumors; EGFR  in two tumors, ERBB2  in three
tumors, and GRB2 in one tumor. A hemizygous deletion of
RASA1, which encodes the Ras-GAP that deactivates H-Ras,
was detected in four tumors.
Table 3
Regions containing a putative homozygous deletion in more than one cell line
Chromosome Region (Mb)a,b CRO (Mb)a,b Cell lines with 
homozygous loss
Tumors with 
hemizygous loss
Genes
8 4.8–7.6 2.8 3 (16.7%) 19 (40%) ANGPT2, LPAAT-e, DEFA1, DEFA3, 
DEFA4, DEFA5, DEFA6, DEFB1, 
DEFB10, DEFT1, SPAG11, DEFB103, 
DEFB104, DEFB105, DEFB106, DEFB4, 
CLDN23
8 10.3–11.7 1.4 2 (%) 6 (13%) UNQ9391, RP1L1, SOX7, PINX1, MTMR9, 
AMAC, TDH, BLK, GATA4, NEIL2
8 19.9–20.0 0.1 2 (11.1%) 15 (32%) PCM1, NAT1, NAT2, EFA6R, ChGn, LPL, 
GFRA2, DOK2, XPO7, NPM2, FGF17, 
EPB49, RAI16
8 23.5–27.5 4.0 2 (11.1%) 17 (36%) TNFRSF10A, EFL, DOCK5, GNRH1, 
KCTD9, EBF2, PPP2R2A, BNIP3L, 
PTK2B
9 0.6–4.2 3.6 2 (11.1%) 9 (19%) ANKRD15, DMRT1, DMRT2, DMRT3, 
SMARCA2, VLDLR, KCNV2, RFX3, 
ZNF515
9 27.6–27.9 0.3 2 (11.1%) 14 (30%) ELAV, PLAA, CCDC2, LRRC19, TEK, 
MOB3B, IFNK
13 72.1–74.0 1.9 2 (11.1%) 6 (13%) KLF12, TBC1D4, UCHL3
18 32.2–37.4 5.2 2 (11.1%) 9 (19%) BRUNOL4
18 38.1–41.8 3.7 3 (16.7%) 13 (28%) RIT2, SYT4, SETBP1
18 46.8–52.8 6.0 2 (11.1%) 6 (13%) MADH4, DCC, MBD2, POLI, STARD6, 
RAB27B, SE57-1, TCF4, TXNL, WDR7
aMap positions and cytogenetic locations containing putative homozygous deletions (intensity ratio <0.5 within a region of hemizygous loss) are 
based on data available from UCSC genome browser (July 2003 freeze) [35]. bRegion boundaries were determined by the next bacterial artificial 
chromosome with different copy number. CRO, common region of overlap.Available online http://breast-cancer-research.com/content/7/6/R1186
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Cooperating genetic loci
As a means of identifying genetic alterations that may function
coordinately in tumor initiation and progression, we looked for
correlation between genetic loci (i.e. for genes that were
gained or lost coordinately with other genes more commonly
than would be expected by chance). Separate correlation
matrices (Fig. 4) were created using the most commonly
altered loci (Table 1). Full heatmaps for genes and loci are
available online [22]. Each matrix was evaluated for positive
correlation (concordant gains or losses) and negative correla-
Table 4
Array-based comparative genomic hybridization validation by DNA quantitative PCR of ERBB2
Tumor ID DNA RNA Protein
aCGH RP11-552K3 Light cycler TaqMan Hercept
Cy3 Cy5 Relative ratio Relative alleles Ratio Staining
40 1.05 1.13 0.67 1 0.51 -
71 1.28 0.58 0.94 2 2.01 -
88 1.48 0.45 1.08 2 2.08 -
268 1.51 0.76 0.94 2 1.78 -
3 1 3 0 . 9 910 . 8 220 . 9 5-
348 1.06 0.8 0.88 2 0.99 -
352 1.64 0.76 0.88 2 n.d.* -
476 1.03 0.88 0.94 2 1.72 -
493 1.25 0.97 0.88 2 n.d. -
277 1.14 0.99 0.94 2 0.67 2+
445 1.42 0.87 0.88 2 0.43 2+
316 2.41 0.43 1.51 3 5.61 3+
369 2.45 0.29 3.88 8 16.1 3+
ERBB2 validation of array-based comparative genomic hybridization (aCGH) DNA copy number using LightCycler Her2/Neu DNA quantification 
kit (Roche), TaqMan Assay on Demand Hs. 00170433_m1 (Applied Biosystems), and protein quantification (Herceptest®). * n.d.: Not done
Figure 3
Genmapp view of the epidermal growth factor (EGF) signaling pathway Genmapp view of the epidermal growth factor (EGF) signaling pathway. Array-based comparative genomic hybridization copy number frequency 
data are represented with gains in green and losses in red.Breast Cancer Research    Vol 7 No 6    Naylor et al.
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tion (discordant gains or losses). To account for the large
number of comparisons, we determined the significance of the
correlation between these loci using the Fisher's exact test to
generate a p-value, again with gains and losses considered
separately.
Although several positive correlations were identified, negative
correlations with p < 0.05 were not found. With the exception
of loci on the same chromosome, only one pair of common
losses was correlated, those on chromosome 4:141.6–145.2
Mb and chr13: 44.6–45.1 Mb (p = 0.004). In contrast, com-
mon regions of gain were highly correlated to one another.
Chromosome 1 and 9 showed the strongest correlation (p <
0.0001), but these loci are also significantly correlated to
many of the other commonly gained loci in the matrix. One
exception is a frequent gain on chromosome16, which is not
correlated to either of these loci, but is highly correlated to
chromosome 17q12 (p = 0.0001).
Discussion
aCGH is a powerful technique that allows determination of
DNA copy number across the genome of a tumor in a single
experiment, with resolution limited only by the number of ele-
ments on the array. As a result, aCGH detects changes at
higher frequency and with smaller CROs than previous
approaches (i.e., chromosomal CGH). Finally, aCGH is semi-
quantitative, providing an opportunity to narrow regions of
copy number gain to those genes most likely to be biologically
significant by identifying infrequent high-level amplifications in
regions of frequent, lower copy number gain, analogous to
using homozygous deletions to narrow larger regions of
hemizygous loss.
Perhaps the most surprising finding of this study is the very
similar pattern of gains and losses in primary tumors and cell
lines. Although there are significantly more frequent genomic
alterations in the cell lines, the pattern of gain and loss is strik-
ingly similar to that seen in the primary tumors. It has long been
thought that cell lines contained substantial amounts of
genomic noise – random, biologically insignificant copy
number alterations considered a reflection of the inherent
genomic instability of human cancers. The current data argue
to the contrary, suggesting that the amplification and deletions
seen in cell lines offer the same growth advantages in cell cul-
ture that they do in vivo, and are similarly selected for over mul-
tiple passages. Furthermore, the relative concordance of
genomic aberrations in cell lines and primary tumors increases
the confidence in the former as relevant in vitro models and
should in the near future allow a direct assessment of how
closely a given cell line reflects the parent genotype from
which it was derived. Finally, these data also suggest that can-
cer genomes are relatively stabile over time, unlike expression
profiles, which can vary dramatically in short periods of time in
response to various growth conditions.
Another surprising finding is the lack of correlation between
prognostic clinical parameters such as stage, grade, and
receptor status and the overall frequency of genome copy
number alterations. A relationship between estrogen receptor
status and both overall genomic aberrations as well as specific
regions of common gains and losses has been recently
reported [14]. Although our data do not confirm their findings,
we cannot exclude the possibility that the relatively small sam-
ple size of this study provided limited power to see these cor-
relations; however, similar results were recently reported with
an aCGH analysis of bladder cancers [23]. If validated in
larger series, these data suggest that it is the specific genetic
changes, not the total number of copy number alterations, that
are determinants of outcome. This hypothesis is consistent
with global expression profiling data in breast cancers, where
altered expression of a small subset of genes in the human
genome was shown to be predictive of outcome years after
Figure 4
Correlations between gained and lost loci in breast cancer Correlations between gained and lost loci in breast cancer. Correlation matrices depicting the interaction between the most frequently gained (a) 
and lost (b) loci in our dataset. Black indicates a p-value > 0.05, whereas the green color becomes more intense as the p-value decreases. Cyto-
band location is indicated, along with the frequency of aberration in parentheses.Available online http://breast-cancer-research.com/content/7/6/R1186
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diagnosis [24]. A larger dataset with longer follow-up than the
current sample set is needed to determine whether a subset
of copy number alterations will be similarly predictive of long
term outcome. As expression profiles are a reflection of the
fixed genetic changes in cancer genomes, however, it is likely
that aCGH profiles of specific gene sets will be similarly pre-
dictive. This would be of great clinical utility, as aCGH may be
performed on archival material, which is much more readily
available than the frozen tumor currently required for expres-
sion profiling. Coupled with the likelihood that fixed genetic
abnormalities in cancer genomes may be more predictive of
response to specific therapy, aCGH holds significant promise
for clinical benefit.
Analysis of some of the most commonly altered regions in this
sample set illustrate the complex pattern of copy number
change that can be clarified with aCGH. For example, the
8q24 amplicon has previously been attributed MYC; however,
aCGH of this sample set detects two distinct regions of ampli-
fication, with the most frequent region of gain being more tel-
omeric to that which includes MYC. Expression profiling of
breast and other epithelial cancers similarly suggested that
MYC  is less frequently overexpressed than genes located
closer to the 8q telomere [25,26]. PTK2 (FAK) falls within this
more telomeric region. PTK2 encodes a cytoplasmic tyrosine
kinase, central to several proliferative pathways, including
integrin, G-protein coupled, and receptor tyrosine kinase sign-
aling, and thus has a plausible role in cancer biology [27].
Consistent with this hypothesis, breast cancer cell lines grown
in monolayer culture frequently express constitutively activated
PTK2, whereas normal mammary epithelial cells grown under
similar conditions do not [28]. In fact, copy number gains of
PTK2 are frequent in cell lines derived from invasive epithelial
tumors, and PTK2 amplification correlates with increased pro-
tein expression in squamous carcinoma cell lines [29].
In addition to increasing the mapping resolution of known
regions of copy number change, aCGH is an unbiased
approach to detecting novel regions of genomic alteration,
which potentially harbor novel cancer-related genes. For
example, these data reveal several novel amplicons on chro-
mosome 1, as well as a narrow region of high-level gain at
1q32.1, which is commonly gained in breast cancer. This
region includes CNTN2, RBBP5, ELK4, Prostein, NUCKS
and two hypothetical genes. Expression profiling of a subset of
these tumors demonstrate that NUCKS  and two ESTs
(Expressed Sequence Tags) are overexpressed in the tumors
with amplifications relative to tumors that are diploid at this
locus. Evidence that NUCKS  (nuclear ubiquitous casein
kinase and cyclin-dependent kinase substrate) is expressed in
breast tissue and is believed to play a role in regulating tran-
scriptional regulation makes it an excellent candidate gene in
this region [30]. The increased resolution of aCGH also
revealed several small regions of modest copy number gain or
hemizygous deletion that have not been associated with
breast tumors in previous studies. Gains at the telomeres of 4p
(4p16.1) and 5p (5p15.33) are examples. While 4p16.1 does
not contain any known cancer-related genes, the catalytic unit
of telomerase (hTERT)  is contained within the 5p15.33
amplicon.
The current data also suggest that homozygous deletions are
relatively uncommon in primary tumors. The only homozygous
deletion we detected in the primary tumors is on chromosome
9p21. This region contains MOB3B, which shares similarity
with the yeast gene scMob1. scMob1 binds Mps1p, a protein
kinase essential for spindle pole body duplication and mitotic
checkpoint regulation, which in turn plays a role in maintaining
genome stability, again providing biological plausibility for loss
of MOB3B in cancer. Homozygous deletions are more com-
mon in cell lines, suggesting positive selection for loss of the
genes in these regions and possibly an increased tolerance to
the loss of adjacent genes in immortalized cell lines. An alter-
native explanation may be that contamination by normal (dip-
loid) cells in primary tumors might decrease the sensitivity of
detection of homozygous losses compared to homogenous
cell lines. As an example, the recurrent homozygous deletion
on 18q21 (46.8–52.8 Mb), which includes SMAD4
(MADH4), also has been observed only in pancreatic cell lines
[31]. Another region of frequent hemizygous loss that contains
a recurrent homozygous deletion in cell lines is 8p23.
Although this region contains 14 genes, 12 of them belong to
the defensin family. Interestingly, defensins play a role in
epithelial wound repair, which involves migration, proliferation
and EGFR activation [32].
A comparison of the relative frequency of gains and losses at
specific loci may provide insight not only into the likelihood that
change at a specific locus is of biological significance, but into
the biological function of the associated genes as well. For
example several tumor suppressor genes known to play a role
in breast cancer, such as RB1, PTEN and BRCA2, were fre-
quently lost, but rarely gained, in our data set. Conversely,
most kinases were gained on average five times more fre-
quently than they were deleted. These data suggest that
regions that are equally likely to be gained and lost are unlikely
to contain genes that confer a selective advantage when
altered. As an example, analysis of copy number changes in
kinases, expected to be amplified in cancers, revealed an inter-
esting relationship between two members of the focal
adhesion kinase family. PTK2  (FAK) is the most frequently
gained gene overall and PTK2B (PYK) is the most frequently
lost kinase. Interestingly, these gene products differentially
regulate progression of the cell cycle, with induction of PTK2B
inhibiting G1-S transition, while induction of PTK2 expression
increases the rate of this transition [33].
Finally, we have used two different methods, pathway mapping
and correlation analysis, to interrogate the aCGH data for evi-
dence of interaction between genomic loci. In this instance,Breast Cancer Research    Vol 7 No 6    Naylor et al.
R1197
pathway mapping suggests that only a subset of the genes in
a pathway may confer a selective advantage when altered in a
specific tissue type. Thus ERBB2, EGFR and GRB2 were fre-
quently amplified, but RAS, RAF and MEK were amplified in
less than 10% of the tumors. Many tumors had more than one
copy number alteration in this pathway, but none had a high
level amplification in more than one node. Only RASA1, which
encodes a Ras-GAP that deactivates H-Ras, was
hemizygously deleted in this pathway. One of the tumors with
a RASA1 deletion did not have a gain in any of the activating
genes in this pathway, suggesting a mechanism of H-Ras acti-
vation in this tumor.
The correlation analysis demonstrated both specific loci that
may cooperate in initiating or maintaining the malignant pheno-
type and some generalized differences between gains and
losses. These observations are consistent with the hypothesis
that gains and losses in cancer genomes are generated by
different mechanisms and subject to different selection. Thus,
when compared to deletions, gains are more common, often
larger, and much more frequently correlated with other gains.
One model of genomic instability that is consistent with these
findings is large scale duplication of the entire genome with
subsequent loss of whole chromosomes or smaller intrachro-
mosomal regions.
The relatively small numbers of patients in each clinical sub-
group did not allow us to identify association between specific
aberrations and clinical characteristics at this time; this may
require both more samples as well as novel analytical methods
to analyze patterns of similar aberrations. In addition to clinical
and histological characteristics, expression profiling is emerg-
ing as a viable means of molecularly subtyping breast cancer,
and a recent report has correlated distinct regions of loss of
heterozygosity with specific expression profiles [34]. Further
work will be required to realize the potential of combining data
from expression analysis and CGH to pinpointing genes
affected by amplifications and deletions, which should lead to
both a better understanding of the significance of specific
genetic aberrations as well as novel targets for therapeutic
interventions.
Conclusion
A set of primary breast cancers and breast cancer cell lines
subjected to aCGH were found to be strikingly similar to one
another and together they generated a rich dataset for inquiry
into the cancer genome. Findings from the analysis of these
data include fine mapping of previously described regions of
gain and loss, identification of novel regions of gain and loss,
and unbiased enumeration of the frequency of copy number
alterations in specific genes. This analysis also was applied to
gene subsets, including kinases and tumor suppressor genes,
and specific pathways, which not only provided a rank order
list of the most common alterations but had apparent func-
tional implications. Finally, correlation analysis identified spe-
cific potential cooperating loci and highlighted possible
differences in genomic mechanisms that generate gains and
losses. These findings require additional investigation but have
the potential to be of substantial biological and therapeutic
significance.
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